Hepatitis-B Clinical Trial

Hepatitis-B Clinical Trial

 

Hepatitis B, an important liver disease, is a common inflammatory disease worldwide. The causative agent of the disease is the hepatitis B virus (HBV). The contagious hepatitis B disease only causes disease in humans. When the virus enters the body, it settles only in the liver cells. The hepatitis B virus leaves the proteins it contains to healthy cells, allowing the immune system to attack these protein molecules. As a result, liver cells are damaged and inflammation begins.
 
According to the World Health Organization, it is estimated that 325 million people in the world are infected with hepatitis B and hepatitis C, and 1.4 million people die annually from causes such as cirrhosis and liver cancer due to viral hepatitis.
 
As AVB Biotechnology, we work on diseases that do not have a cure and/or take a long time to treat. Hepatitis B is one of them. Clinical trial preparations have been completed.